 Sodium Glucose Cotransporter II, SGLT2, inhibitors are becoming increasingly popular as they show promising cardiovascular and renal benefits in patients with type 2 diabetes. These drugs can also be used in patients with acute myocardial infarction, acute heart failure, RV failure, LVAD, and type 1 diabetes. The mechanism behind the cardiovascular benefits of SGLT2 inhibitors is not fully understood but may involve reducing blood pressure and glucose levels, improving insulin sensitivity, and decreasing inflammation. This article was authored by Gasan Modi, Tuvia Bengal, and Shaal Adder.